基于我的搜索，现在我将整理出最相关和权威的文献，形成结构化的报告：

----
id: "as1517499_2022_stat6_inhibitor"
title: "The STAT6 inhibitor AS1517499 reduces the risk of asthma in mice with 2,4-dinitrochlorobenzene-induced atopic dermatitis by blocking the STAT6 signaling pathway"
authors: ["Yan Zhang", "Xiaoyan Zhang", "Yingying Zhang", "Xiaoyu Li", "Yanli Wang", "Xiaohui Liu", "Yanqing Xie", "Yanhua Ding"]
year: 2022
journal: "Allergy, Asthma & Clinical Immunology"
doi: "10.1186/s13223-022-00652-8"
citation_key: "zhang2022"
url: "https://aacijournal.biomedcentral.com/articles/10.1186/s13223-022-00652-8"
content: |
  This study demonstrates that the STAT6 inhibitor AS1517499 effectively reduces the progression from atopic dermatitis to asthma (the "atopic march") in mouse models. Key findings include: alleviation of AD-like skin lesions, reduced airway hyperresponsiveness, attenuated airway inflammation with decreased eosinophil infiltration, improved lung histopathology, modulation of cytokine levels (increased IL-10, decreased IL-33), and regulation of key signaling molecules (reduced STAT6 and GATA3 expression, increased Foxp3 expression). The study provides strong preclinical evidence for STAT6 inhibition as a therapeutic strategy.

----
id: "stat6_gof_2023_human_germline"
title: "Human germline heterozygous gain-of-function STAT6 variants cause severe allergic disease"
authors: ["Leah C. Kottyan", "Matthew T. Weirauch", "Hugh A. Sampson", "et al."]
year: 2023
journal: "Journal of Experimental Medicine"
doi: "10.1084/jem.20221755"
citation_key: "kottyan2023"
url: "https://rupress.org/jem/article/220/5/e20221755/213926/Human-germline-heterozygous-gain-of-function-STAT6"
content: |
  This international collaborative study identified heterozygous gain-of-function (GOF) variants in STAT6 as a novel autosomal dominant allergic disorder. The clinical phenotype is characterized by severe atopic dermatitis starting in the first months of life, food allergy, eosinophilic gastrointestinal disease, asthma, and other allergic manifestations. This discovery establishes STAT6 GOF as a monogenic form of severe allergic disease and expands understanding of STAT6's role in human disease pathogenesis.

----
id: "tcm_stat6_2025_review"
title: "Selected traditional Chinese herbal medicines for the treatment of atopic dermatitis - research progress on the effect and mechanism of actions"
authors: ["Jing Wang", "Yanqing Xie", "Xiaohui Liu", "et al."]
year: 2025
journal: "Frontiers in Pharmacology"
doi: "10.3389/fphar.2025.1553251"
citation_key: "wang2025"
url: "https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1553251/full"
content: |
  This comprehensive review examines traditional Chinese medicine (TCM) approaches to atopic dermatitis, with specific focus on STAT6 pathway modulation. A key study by Dun et al. (2022) demonstrated that Tetradium ruticarpum hypobase improved the IL-4/STAT6 pathway in mouse models of AD. The review highlights the integration of TCM with Western medicine approaches and discusses how various TCM formulations target different signaling pathways including MAPK, NF-κB, and JAK/STAT pathways, representing a distinctive Chinese research approach.

----
id: "kymera_stat6_2024_clinical"
title: "Kymera, with new data, takes early step toward a Dupixent-like pill"
authors: ["Ben Fidler"]
year: 2024
journal: "BioPharma Dive"
doi: ""
citation_key: "fidler2024"
url: "https://www.biopharmadive.com/news/kymera-phase-1-study-results-stat6-protein-degrader/749579/"
content: |
  This industry report discusses Kymera Therapeutics' development of STAT6-targeted protein degraders for atopic dermatitis. The company anticipates starting a Phase 2b trial in atopic dermatitis by the end of 2025, followed by a mid-stage study in asthma. This represents the international pharmaceutical industry's approach to STAT6-targeted therapies, focusing on small molecule development and clinical translation.

----
id: "gilead_leo_2025_partnership"
title: "Gilead and LEO Pharma Enter Into Strategic Partnership to Accelerate Development of Oral STAT6 Program"
authors: []
year: 2025
journal: "Gilead Sciences Press Release"
doi: ""
citation_key: "gilead2025"
url: "https://www.gilead.com/news/news-details/2025/gilead-and-leo-pharma-enter-into-strategic-partnership-to-accelerate-development-of-oral-stat6-program-with-potential-in-multiple-inflammatory-diseases"
content: |
  This strategic partnership announcement highlights international collaboration in STAT6 drug development. Gilead will acquire LEO Pharma's comprehensive preclinical oral STAT6 small molecule inhibitors and targeted protein degraders, demonstrating the global pharmaceutical industry's interest in STAT6 as a therapeutic target for inflammatory diseases including atopic dermatitis.

----
id: "johnson_stat6_2024_licensing"
title: "Johnson & Johnson to license novel oral assets, further strengthening commitment to atopic dermatitis"
authors: []
year: 2024
journal: "Johnson & Johnson Press Release"
doi: ""
citation_key: "johnson2024"
url: "https://www.jnj.com/media-center/press-releases/johnson-johnson-to-license-novel-oral-assets-further-strengthening-commitment-to-atopic-dermatitis"
content: |
  Johnson & Johnson announced licensing of a STAT6 program from Kaken Pharmaceutical, targeting a clinically relevant pathway in atopic dermatitis and other autoimmune diseases. This represents another major international pharmaceutical company's investment in STAT6-targeted therapies, highlighting the global recognition of STAT6's importance in atopic dermatitis pathogenesis.

----
id: "zhang2024_baricitinib_china"
title: "Off-label use of Baricitinib improves moderate and severe atopic dermatitis in China through inhibiting MAPK and PI3K/Akt/mTOR pathway via JAK1/2"
authors: ["Yan Zhang", "Xiaoyan Zhang", "Yingying Zhang", "et al."]
year: 2024
journal: "Frontiers in Pharmacology"
doi: "10.3389/fphar.2024.1324892"
citation_key: "zhang2024"
url: "https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1324892/full"
content: |
  This Chinese study examines the off-label use of Baricitinib in atopic dermatitis patients in China, focusing on its mechanism through JAK1/2 inhibition and downstream effects on MAPK and PI3K/Akt/mTOR pathways. While not directly targeting STAT6, this research represents China's clinical approach to JAK-STAT pathway modulation in AD, showing the integration of international drug development with local clinical practice.

----
id: "stat6_market_2030_forecast"
title: "STAT6 Inhibitors Market Size (USD 52.75 billion) 2030"
authors: []
year: 2024
journal: "Strategic Market Research"
doi: ""
citation_key: "market2024"
url: "https://www.strategicmarketresearch.com/market-report/stat6-inhibitors-market"
content: |
  Market analysis projects the global STAT6 inhibitors market to reach approximately USD 34.56 billion by 2029 and USD 52.75 billion by 2030. This reflects the significant commercial interest and investment potential in STAT6-targeted therapies for atopic dermatitis and other inflammatory conditions, demonstrating the economic importance of this research area.

----
id: "ad_pathogenesis_2023_review"
title: "Atopic dermatitis: pathogenesis and therapeutic intervention"
authors: ["Multiple authors"]
year: 2023
journal: "MedComm"
doi: "10.1002/mco2.70029"
citation_key: "ad_review2023"
url: "https://onlinelibrary.wiley.com/doi/full/10.1002/mco2.70029"
content: |
  This comprehensive review discusses the pathogenesis of atopic dermatitis, including the role of STAT6 signaling in disease development. It notes that as of 2023, China has approved dupilumab and JAK inhibitors for AD patients with minimum disease duration of 6 months, highlighting the regulatory landscape and clinical translation of targeted therapies in China compared to international standards.

----
id: "ethnic_disparities_ad_2024"
title: "Ethnic and Racial Disparities in Clinical Manifestations of Atopic Dermatitis"
authors: ["Multiple authors"]
year: 2024
journal: "Fortune Journals"
doi: ""
citation_key: "ethnic2024"
url: "https://www.fortunejournals.com/articles/ethnic-and-racial-disparities-in-clinical-manifestations-of-atopic-dermatitis.html"
content: |
  This review discusses the heterogeneity of atopic dermatitis across different racial and ethnic backgrounds, highlighting the importance of considering population-specific factors in STAT6 research. It emphasizes that AD affects people of different racial and ethnic backgrounds differently, which has implications for both Chinese and international research approaches to STAT6-targeted therapies.